Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2011/04/001672
CTRI/2011/04/001672
Completed
Phase 4

Assessment of Efficacy, Safety and Tolerability of Fixed Dose Combination Wunder Eye Cream (3% Biophytex LS 8740 an 5% Proteasyl TP LS 8657) in the treatment of under Eye Dark Circles. - NI

Glenmark Pharmaceuticals Limited0 sites20 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Glenmark Pharmaceuticals Limited
Enrollment
20
Status
Completed
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •?Subjects with mild, moderate or severe under eye dark circles
  • •?Subjects must be 18\-50 years of age
  • •?Both males and females
  • •?Subjects with no history of glaucoma, any eye infection and with normal range of intraocular pressure
  • •?Subjects must provide written informed consent and comply to the protocol
  • •?Wash out period of 14 or more days prior to enrollment in case of subjects using any other skin care products.

Exclusion Criteria

  • •?Subjects not willing to discontinue all topical treatments for ?Under Eye? dark circles for 2 weeks prior to enrollment in study
  • •?Hypersensitivity to any ingredients of Wunder Eye cream
  • •?Pregnant and lactating women
  • •?Subjects taking Concomitant therapy that might interfere with the study results
  • •?Subjects with dermatological disorder of face that may interfere with study evaluation
  • •?Subjects who have undergone any surgical treatment of the face
  • •?Subjects with abnormal intraocular pressure, history of glaucoma and any eye infection on ophthalmological examination
  • •?Concomitant topical therapy in under eye area that causes hypopigmentation includes Retinoids and Hydroquinone skin peels.
  • •?Concomitant medicines, that cause hyper pigmentation, include Phenothiazines, Anti\-malarials (Chloroquine), Phenytoin sodium, cytotoxic drugs, Sulphonamides.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 4
A Clinical trial to study the effects and tolerability of Dacne gel containing Clindamycin Phosphate 1% and zinc acetate in patients suffering from acne.
CTRI/2011/091/000041Glenmark Pharmaceuticals Ltd125
Completed
Phase 4
A clinical trial to study the effect of Hair4U 10% containing (minoxidil 10% plus Aminexil 1.5%)in treatment of male pattern of baldnessHealth Condition 1: null- Androgenetic Alopecia
CTRI/2011/06/001813Glenmark Pharmaceuticals Ltd75
Completed
Not Applicable
Observational Study on cough syrupHealth Condition 1: null- productive cough (cough with expectoration) associated with any of the nasal symptoms (nasal discharge,nasal stuffiness, nasal itching, and Sneezing) since at least previous 8 hours
CTRI/2015/09/006198Dr Reddys laboratories Ltd250
Completed
Phase 4
Study of Efficacy, Safety and Tolerability of Na-Picosulphate in patients requiring anorectal surgeryHealth Condition 1: null- Patients requiring bowel preparation for gastrointestinal or anorectal surgery
CTRI/2016/09/007292VYAS SURGERY100
Recruiting
Phase 4
Assessment of Steroneo Skin Cream (Physalis Angulata Supercritical Extract) application for treatment of eczematous lesions
CTRI/2016/11/007511Rehmat Clinic50